ATS Medical Announces Participation in the Annual Meeting of the American Association for Thoraci...( MINNEAPOLIS May 7 /- ATS Medical Inc....)

MINNEAPOLIS, May 7 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced participation in the upcoming 89th Annual Meeting of the American Association for Thoracic Surgeons (AATS) being held in Boston from May 10-13, 2009. The Annual AATS meeting is key gathering of cardiovascular surgeons, nurses and allied health professionals from around the world that provides an excellent venue for the Company to exhibit its growing portfolio of clinically relevant products designed to meet the needs of cardiac surgeons and their patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO)

Highlighting ATS's broad product offering is the ATS 3f(R) Aortic Bioprosthesis designed to replace the patient's diseased valve. The ATS 3f Aortic Bioprosthesis is a revolutionary next generation stentless pericardial aortic tissue valve that is unlike any other valve with its tubular design that restores continuity between the annulus and the sinotubular junction. By restoring this continuity, the ATS 3f Aortic Bioprosthesis is the only aortic valve that preserves the sinuses and restores native valve stress distribution and physiologic blood flow. This valve design provides surgeons and patients with a potentially more durable solution to aortic valve replacement. In addition, ATS is sponsoring a symposium on Sunday, May 10th at 7:00 pm at the Skywalk Observatory in the Prudential Tower entitled, "The ATS 3f Revolution," which will be hosted by several preeminent cardiac surgeons including Richard Shemin, MD, from UCLA, Los Angeles, Allan Stewart, MD, from Columbia University Medical Center, New York, and Sven Martens, MD, from JW
'/>"/>